10-Q: Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Clinical Program Update

Trevi Therapeutics reports a net loss of $23.3 million for the first half of 2024, while advancing clinical trials for Haduvio.

Summary

• Trevi Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $23.3 million for the six months ended June 30, 2024.
• The company's operating expenses totaled $25.2 million for the same period, with research and development accounting for $18.8 million.
• Trevi's cash, cash equivalents, and marketable securities amounted to $69.5 million as of June 30, 2024.
• The company believes its current resources will fund operations into 2026.
• Trevi is actively progressing clinical trials for Haduvio, including the Phase 2b CORAL trial for chronic cough in IPF, the Phase 2a RIVER trial for refractory chronic cough, and the Phase 1b TIDAL study for respiratory physiology in IPF patients.
• A human abuse potential study is also underway, with topline data expected in the fourth quarter of 2024.
• The company has not generated any revenue from product sales and has incurred net losses since its inception.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is making progress in its clinical trials and has sufficient funding for the near term, it is also experiencing significant losses and faces substantial risks and uncertainties. The need for additional funding and the dependence on a single product candidate are also concerning.

Positives

• The company has sufficient cash, cash equivalents, and marketable securities to fund operations into 2026.
• Clinical trials for Haduvio are progressing, with key data readouts expected in the near term.
• The company is actively managing its financial resources and advancing its clinical programs.

Negatives

• The company has incurred significant losses since inception and expects to continue to incur losses for the foreseeable future.
• Trevi has not generated any revenue from product sales.
• The company is dependent on the successful development and commercialization of Haduvio, its sole product candidate.
• The company will need substantial additional funding to support its continuing operations.

Risks

• The company is dependent on the successful development and commercialization of Haduvio, and any delays or failures could significantly harm the business.
• Clinical trials may not be predictive of success in later trials, and Haduvio may not show the desired safety and efficacy.
• The company may experience delays or difficulties in enrolling patients in clinical trials.
• Adverse events or side effects of Haduvio could delay or prevent marketing approval.
• The drug label for nalbuphine carries an opioid class label warning for respiratory depression, which could lead to additional trials or labeling restrictions.
• If the results of the HAP study suggest that Haduvio may carry risks of misuse, abuse or addiction, the FDA may require a Risk Evaluation and Mitigation Strategy.
• The company faces substantial competition, which may result in others developing or commercializing products before or more successfully than Trevi.
• The company relies on third parties for clinical trials and manufacturing, and their performance could impact the business.
• The number of shares of common stock underlying outstanding warrants is significant, which could negatively affect the market price of the stock.

Future Outlook

The company expects to incur substantial expenditures in the foreseeable future as it advances Haduvio through clinical development, the regulatory approval process, and potential commercial launch activities. Trevi believes its existing cash, cash equivalents, and marketable securities will enable it to fund operating expenses and capital expenditure requirements into 2026.

Management Comments

• The company believes that Haduvio has the potential to be effective in treating cough that originates from a variety of medical conditions.
• The company plans to request an end of Phase 2 meeting with the FDA for the prurigo nodularis program.
• The company does not intend to complete the development of Haduvio for prurigo nodularis itself, and may seek to enter into a strategic collaboration for the continued development of this program.

Industry Context

The document highlights the competitive landscape in the development of treatments for chronic cough in IPF and RCC, noting that other companies are also conducting clinical trials in these areas. The company also notes that many patients use various treatments off-label to treat chronic cough associated with IPF and RCC, and these patients and their physicians may be reluctant to forgo, discontinue or otherwise alter their use of such off-label therapeutic approaches to participate in our clinical trials.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards for financial metrics.
• The document notes that many pharmaceutical and biotechnology companies have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, which is a common risk in the industry.
• The document mentions that the drug label for nalbuphine carries an opioid class label warning for serious, life-threatening or fatal respiratory depression, which is consistent with the known risks of opioid medications.
• The document notes that many currently approved -opioid products are subject to restrictive marketing and distribution regulations, which is a common regulatory challenge for this class of drugs.

Related Party Transactions

• On October 18, 2021, the Company issued and sold to New Enterprise Associates 16, L.P., an existing stockholder of the Company (NEA) and related party, in a private placement, 1,851,852 shares of the Companys common stock and accompanying warrants to purchase an aggregate of 3,703,704 shares of the Companys common stock.
• NEA, an existing stockholder of the Company and a related party, as well as an affiliate of NEA, participated in the April 2022 Private Placement.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential losses due to stock price volatility.
• Employees may be affected by the company's financial performance and potential changes in operations.
• Patients may benefit from the development of new treatments for chronic cough and prurigo nodularis, but face risks associated with clinical trials and potential side effects.
• Suppliers and creditors face risks associated with the company's financial stability and ability to meet its obligations.

Next Steps

• The company expects a sample size re-estimation analysis for the Phase 2b CORAL trial in the fourth quarter of 2024.
• Topline data from the Phase 2b CORAL trial is expected in the first half of 2025.
• Topline data from the Phase 2a RIVER trial is expected in the fourth quarter of 2024.
• Topline data from the human abuse potential study is expected in the fourth quarter of 2024.
• The company plans to request an end of Phase 2 meeting with the FDA for the prurigo nodularis program.
• The company will determine next steps with respect to its prurigo nodularis program, including with respect to the conduct of any future Phase 3 clinical trial.

Key Dates

Keywords

Haduvio, chronic cough, idiopathic pulmonary fibrosis, refractory chronic cough, clinical trials, nalbuphine, biopharmaceutical, research and development, regulatory approval, prurigo nodularis